Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
about
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Identification of a novel HLA-A 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene.The role of adipose-derived stem cells in breast cancer progression and metastasis.Resistance to targeted cancer drugs through hepatocyte growth factor signalingCancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptorsExpression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancerIdentification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancerTherapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome.A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer
P2860
Q33737278-BA6A6381-AC0F-4C5A-9E3E-EA6DE8AFFA6EQ33793930-861E007C-1983-4580-9857-B659D4E2E363Q35592378-DD22794A-D9C8-4B77-8642-455DCD8037D8Q36189390-D1A6072E-09AC-4D59-8588-659A2707ECE0Q36544839-FC2A2BFF-D232-4D10-8550-77E188CB3026Q36777139-09A5B643-726B-4F5F-93CD-7122DB5F6285Q36898399-89D28C25-62AC-4660-9D5E-605FEA3FD5B6Q36998301-D359076F-69D3-4E1F-A33B-2E7D4E9E7B6FQ37588298-1B5B7FE7-B8E6-4EDF-B8C9-B138BEE86CD3Q38214802-0AF7C9E9-CBD9-4D61-B467-EA3D9581DD9BQ38238613-81A8070D-421E-498F-A5B9-CA2B0A6584AAQ38812867-EF44E264-EAD7-4E36-AF5E-EA8416F72529Q38968841-8D91BDEC-3E3E-4989-A73E-DF8FAB3E78DBQ39016680-A7CF3F27-8821-4D19-B492-BEB7FD1A3056Q40592492-F1FFC29F-6A59-456F-88FE-82483385B9B5Q48134448-F127233E-AB65-476B-83C2-C42F47C38EB5Q58719654-B5A3E691-0E3F-4C9D-B8D4-D33F2B14D923
P2860
Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
name
Spontaneous epithelial-mesench ...... ositive luminal breast cancer.
@ast
Spontaneous epithelial-mesench ...... ositive luminal breast cancer.
@en
type
label
Spontaneous epithelial-mesench ...... ositive luminal breast cancer.
@ast
Spontaneous epithelial-mesench ...... ositive luminal breast cancer.
@en
prefLabel
Spontaneous epithelial-mesench ...... ositive luminal breast cancer.
@ast
Spontaneous epithelial-mesench ...... ositive luminal breast cancer.
@en
P2093
P2860
P1433
P1476
Spontaneous epithelial-mesench ...... ositive luminal breast cancer.
@en
P2093
Bassam Abdulkarim
David Lesniak
Kathryn Graham
Mavanur Suresh
Pravin Bhatnagar
Yaoxian Xu
P2860
P304
P356
10.1371/JOURNAL.PONE.0071987
P407
P50
P577
2013-08-26T00:00:00Z